(Q34568196)

English

Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

treatment-resistant depression

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Mark Hyman Rapaport

1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Georges M Gharabawi

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Carla M Canuso

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Ramy A Mahmoud

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Martin B Keller

5

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Cynthia A Bossie

6

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Ibrahim Turkoz

7

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Robert A Lasser

8

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Amy Loescher

9

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Philippe Bouhours

10

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Fiona Dunbar

11

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Charles B Nemeroff

12

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

language of work or name

0 references

publication date

7 June 2006

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Neuropsychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

2505-2513

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

https://scigraph.springernature.com/pub.10.1038/sj.npp.1301113

0 references

Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301113

21 January 2018

Treatment algorithms in treatment-resistant depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301113

21 January 2018

A rating scale for drug-induced akathisia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301113

21 January 2018

Psychotherapy alone and combined with pharmacotherapy in the treatment of depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301113

21 January 2018

Evidence based review of escitalopram in treating major depressive disorder in primary care

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301113

21 January 2018

Six-year outcome of cognitive behavior therapy for prevention of recurrent depression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301113

21 January 2018

Definition and epidemiology of treatment-resistant depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301113

21 January 2018

The use of rapid-rate transcranial magnetic stimulation (rTMS) in refractory depressed patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301113

21 January 2018

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301113

21 January 2018

A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301113

21 January 2018

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301113

21 January 2018

Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301113

21 January 2018

A novel augmentation strategy for treating resistant major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301113

21 January 2018

ECT of major depressed patients in relation to biological and clinical variables: a brief overview

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301113

21 January 2018

Cross-national epidemiology of major depression and bipolar disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301113

21 January 2018

Treatment-resistant depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301113

7 January 2021

based on heuristic

inferred from DOI database lookup

Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301113

7 January 2021

based on heuristic

inferred from DOI database lookup

A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301113

7 January 2021

based on heuristic

inferred from DOI database lookup

Risperidone augmentation of selective serotonin reuptake inhibitors in major depression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301113

7 January 2021

based on heuristic

inferred from DOI database lookup

Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301113

7 January 2021

based on heuristic

inferred from DOI database lookup

Escitalopram continuation treatment prevents relapse of depressive episodes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301113

7 January 2021

based on heuristic

inferred from DOI database lookup

Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301113

7 January 2021

based on heuristic

inferred from DOI database lookup

Psychosocial impairment and recurrence of major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301113

7 January 2021

based on heuristic

inferred from DOI database lookup

Citalopram treatment of fluoxetine nonresponders.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301113

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.NPP.1301113

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Dimensions Publication ID

0 references

release_an3pyil5ozeezjxjqjquj27yoe

1 reference

https://api.fatcat.wiki/v0/release/an3pyil5ozeezjxjqjquj27yoe

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34568196&oldid=1843410680"